A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSIO

Phase 1

• Conditions: Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]; Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (WHO Group I CTD-PAH)

• Registration Number: EUCTR2016-000196-24-BE
• Lead Sponsor: Reata Pharmaceuticals, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-07-11
• Last Update Posted: 1 February 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 130

Inclusion Criteria

1. Adult male and female patients = 18 to = 75 years of age upon study consent;
2. BMI > 18.5 kg/m2;
3. Symptomatic pulmonary hypertension WHO/NYHA FC class II and III;
4. WHO Group I PAH associated with connective tissue disease;
5. Had a diagnostic right heart catheterization performed and documented within 36 months prior to Day 1 that confirmed a diagnosis of PAH according to all the following criteria:
a. Mean pulmonary artery pressure = 25 mm Hg (at rest);
b. Pulmonary capillary wedge pressure (PCWP) = 15 mm Hg;
c. Pulmonary vascular resistance > 240 dyn•sec/cm5 or > 3 mm Hg/liter (L)/minute;
6. Has BNP level = 400 pg/mL;
7. Had an average 6MWD = 150 meters on two consecutive tests performed on different days prior to randomization, with both tests measuring within 15% of one another;
8. Has been receiving no more than two (2) approved disease-specific PAH therapies. PAH therapy must have been at a stable dose for at least 90 days prior to Day 1. No additions or changes should be made to PAH therapies and doses should remain stable for the duration of the study;
9. Has maintained a stable dose for 30 days prior to Day 1 if receiving any of the following therapies that may affect PAH: vasodilators (including calcium channel blockers), digoxin, L-arginine supplementation, or oxygen supplementation. No additions or changes should be made to therapies and doses should remain stable for the duration of the study;
10. If receiving treatment for CTD with prednisone or any other drugs, doses must remain stablefor at least 30 days prior to Day 1 and for the duration of the study;
11. Had pulmonary function tests (PFTs) within 90 days prior to Day 1 with total lung capacity = 65% (predicted);
12. Had a ventilation-perfusion (V/Q) lung scan, spiral/helical/electron beam computed tomography (CT), or pulmonary angiogram prior to Day 1 that shows no evidence of thromboembolic disease (i.e., should note normal or low probability for pulmonary embolism). If V/Q scan was abnormal (i.e., results other than normal or low probability), then a confirmatory CT or selective pulmonary angiography must exclude chronic thromboembolic pulmonary hypertension;
13. Has adequate kidney function defined as an estimated glomerular filtration rate (eGFR) = 45 mL/min/1.73 m2 as measured by the central lab;
14. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
15. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study prior to initiation of any patient-mandated procedures.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 117
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 13

Exclusion Criteria

1. Participation in other investigational clinical studies involving interventional products being tested or used in a way different from the approved form or when used for an unapproved indication within 30 days prior to Day 1;
2. Initiation of an exercise program for cardio-pulmonary rehabilitation within 90 days prior to Day 1 or planned initiation during the study;
3. Stopped receiving any PAH chronic therapy within 60 days prior to Day 1;
4. Received a dose of prednisone > 20 mg/day (or equivalent dose if other corticosteroid) within 30 days prior to Day 1;
5. Received intravenous (iv) or subcutaneous (sc) prostacyclin/prostacyclin analogues within 90 days prior to Day 1;
6. Received intravenous inotropes within 30 days prior to Day 1;
7. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) > 160 mm Hg or sitting diastolic BP > 100 mm Hg during Screening after a period of rest;
8. Has systolic BP < 90 mm Hg during Screening after a period of rest;
9. Has a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease, including but not limited to any of the following: a. Congenital or acquired valvular disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension; b. Pericardial constriction; c. Restrictive or congestive cardiomyopathy; d. Left ventricular ejection fraction < 40% per echocardiogram (ECHO) within 90 days of Day 1; e. Symptomatic coronary artery disease within the last 3 years;
10. Acutely decompensated heart failure within 30 days prior to Day 1, per investigator assessment;
11. Has more than two of the following clinical risk factors for left ventricular diastolic dysfunction: a. Age > 65 years; b. BMI = 30 kg/m2; c. History of systemic hypertension; d. History of type 2 diabetes; e. History of atrial fibrillation;
12. History of atrial septostomy within 180 days prior to Day 1;
13. History of uncontrolled obstructive sleep apnea;
14. Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C);
15. Serum aminotransferase (ALT or AST) levels > 1.5X the upper limit of normal (ULN) at Screening;
16. Hemoglobin (Hgb) concentration < 8.5 g/dL at Screening;
17. Diagnosis of Down syndrome;
18. History of malignancy within 5 years prior to Screening, with the exception of localized skin or cervical carcinomas;
19. Untreated or uncontrolled active bacterial, fungal, or viral infection;
20. Known or suspected active drug or alcohol abuse, per investigator judgment;
21. Use of Herbalife supplements within 14 days prior to Day 1;
22. Use of inhaled nitric oxide within 7 days prior to Screening and Day 1 visits, excluding acute vasodilator testing during diagnostic cardiac catheterization;
23. Major surgery within 30 days prior to Day 1 or planned to occur during the course of the study;
24. Unwilling to practi

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To assess the efficacy of bardoxolone methyl relative to placebo.;Secondary Objective: To assess the safety of bardoxolone methyl relative to placebo;Primary end point(s): Change from baseline in six-minute-walk distance (6MWD) relative to placebo at week 24.;Timepoint(s) of evaluation of this end point: Six minute walk test will be performed at screening, baseline, weeks 4, 8, 16, 24, End of treatment (if applicable) and Follow-up visit (week 28). Change from baseline will be calculated by comparing results at Day 1 and Week 24.